Phase II study of capecitabine and interferon-alpha in metastatic renal cell carcinoma patients with failure on interleukin-2 based regimens.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Capecitabine; Interferon alpha
- Indications Renal cancer
- Focus Therapeutic Use
- 06 May 2009 Planned number of patients changed from 48 to 49 Last checked against ClinicalTrials.gov record.
- 06 May 2009 Actual initiation date changed from Oct 2007 to Dec 2006 as reported by ClinicalTrials.gov.
- 06 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.